Mesothelioma
A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)
Subtype terms (2)
More specific conditions that are subtypes of Mesothelioma in the MeSH hierarchy.
- Mesothelioma, Cystic
- Mesothelioma, Malignant
131 drugs (66 approved, 65 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (1)
Phase 3 trials (14)
Phase 2 trials (110)
- anlotinib
- rilotumumab
- anetumab ravtansine
- apg-115
- autologous tumor infiltrating lymphocytes
- autologous wt1-tcrc4 gene-transduced cd8-positive tcm/tn lymphocytes
- avelumab
- olaparib
- urea
- sorafenib
- bay94-9392
- belinostat
- biw-8962
- cixutumumab
- dec-205/ny-eso-1 fusion protein cdx-1401
- dovitinib
- doxorubicin
- folic acid
- gc1008
- fluorouracil
- paclitaxel
- imatinib
- naltrexone
- aldesleukin
- cyanocobalamin
- ramucirumab
- lenvatinib
- lmb-100
- lurbinectedin
- milataxel
- +80 more
Phase 1 trials (80)
- decitabine
- azacitidine
- aglatimagene besadenovec
- allogeneic natural killer cells
- mkc1106
- talazoparib
- irinotecan
- car t cells
- Numidargistat
- cb-839
- tofacitinib
- crs-207
- cannabidiol
- enzalutamide
- rifampin
- hyperpolarized helium
- xenon-129
- icasp9m28z t cell infusions
- bosutinib
- Eganelisib
- mgd009
- amatuximab
- s-588210
- oncolytic measles virus encoding thyroidal sodium iodide symporter
- palbociclib
- panobinostat
- prostate specific membrane antigen
- temozolomide
- autologous tumor cell vaccine
- valaciclovir
- +50 more
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (41)
- Bristol-Myers Squibb
- Roche
- AstraZeneca
- Merck
- MolMed S.p.A.
- Polaris Group
- Tamir Biotechnology, Inc.
- Boehringer Ingelheim
- PrECOG, LLC.
- Medical Research Council
- National Cancer Institute (NCI)
- Velindre NHS Trust
- University of Pennsylvania
- University of London
- Cornell University
- European Thoracic Oncology Platform
- Intergroupe Francophone de Cancerologie Thoracique
- Johns Hopkins University
- NRG Oncology
- New York University
- Queen's University, Belfast
- Sheffield Hallam University
- University of Glasgow
- University of Leeds
- University of Leicester
- University of Sydney
- Groupe Francais De Pneumo-Cancerologie
- Groupe Hospitalier Paris Saint Joseph
- Royal Marsden Hospital NHS Trust
- European Organisation for Research and Treatment of Cancer
- +11 more
Organization Involved with Phase 2 Indications (133)
- Pierre Fabre
- Seattle Genetics
- Millennium Pharmaceuticals
- Clovis Oncology
- Morphotek
- Genentech
- MedImmune
- Genzyme
- Pfizer
- Sanofi
- Novartis
- Bayer
- CanBas Co. Ltd.
- Kissei Pharmaceuticals
- Kyowa Hakko Kirin
- Momotaro-Gene Inc.
- NovoCure Ltd.
- Oshadi Drug Administration
- Shenzhen BinDeBio Ltd.
- Sorrento Therapeutics, Inc.
- Targovax ASA
- Taxolog Inc.
- Theradex
- Verastem, Inc.
- BerGenBio ASA
- Epizyme, Inc.
- PharmaMar
- Tesaro
- Swiss National Science Foundation
- The Christie NHS Foundation Trust
- +103 more
Organization Involved with Phase 1 Indications (47)
- Incyte
- Genelux
- Celgene
- Advanced Accelerator Applications
- Candel Therapeutics
- Schering-Plough
- Shionogi
- Biogen
- Anza Therapeutics, Inc.
- Ascentage Pharma Group Inc.
- Atara Biotherapeutics
- Infinity Pharmaceuticals, Inc.
- Innovive Pharmaceuticals
- MacroGenics
- Oncovir, Inc.
- Asbestos Diseases Research Foundation
- Vastra Gotaland Region
- Huazhong University of Science and Technology
- Augusta University
- Temple University
- Istituto Nazionale per lo Studio e la Cura dei Tumori
- Lakehead University
- University of Kentucky
- Stony Brook University
- University of California, San Diego
- University of Cincinnati
- Icahn School of Medicine at Mount Sinai
- Calithera Biosciences
- Xencor
- Accord Research
- +17 more
Organization Involved with Other Experimental Indications (2)